ArticleFrontiers in digital health2026
Artificial intelligence tool utilization in deprescribing practices among community pharmacists in Jordan: a cross-sectional study.
Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Data on artificial intelligence-supported deprescribing in Jordanian community pharmacy are still lacking. This study aimed to assess current deprescribing practices among community pharmacists in Jordan, identify the medication classes most commonly targeted for deprescribing, evaluate perceived outcomes, and determine factors associated with AI tool use in deprescribing. Methods: This was a cross-sectional survey-based study conducted among licensed community pharmacists in Jordan from 15 November 2025 to 15 March 2026 using online, in-person, and telephone recruitment. The questionnaire assessed participant and practice characteristics, deprescribing activities, digital infrastructure, and use of AI tools. For the primary analysis, AI use was operationalized specifically as self-reported AI-chatbot use, whereas other computerized decision-support tools were reported separately. The SPSS (version 29) was used to conduct descriptive statistics, chi-square tests, and multivariable logistic regression. Results: Of the 1,036 pharmacists who completed the questionnaire, 798 (77.0%) reported practicing deprescribing. The medication classes most frequently reported as targets of deprescribing-related activity were antibiotics (799, 77.1%), proton-pump inhibitors (790, 76.3%), vitamins and mineral supplements (776, 74.9%), non-opioid analgesics/nonsteroidal anti-inflammatory drugs (753, 72.7%), and antidiabetic drugs (638, 61.6%). More than half of the pharmacists (641, 61.9%) reported using a digital tool to identify deprescribing opportunities and (340, 32.8%) reported using AI chatbot. Frequently observed outcomes after deprescribing were better patient-reported health (429, 41.4%), improved adherence (417, 40.3%), and fewer side effects (417, 40.3%), whereas worsening of symptoms was reported less often (89, 8.6%). AI use was independently associated with male gender (adjusted odds ratio [AOR] 1.32, 95% confidence interval [CI] 1.01-1.73), PharmD qualification versus BPharm/BSc (AOR 1.38, 95% CI 1.02-1.87), urban practice versus rural practice (AOR 1.52, 95% CI 1.04-2.22), and reliable internet access (AOR 3.89, 95% CI 1.95-7.76). Conclusion: Deprescribing is widely reported in Jordanian community pharmacy practice, and one-third of pharmacists use AI chatbots to support deprescribing decisions. Strengthening internet access, targeted training, and equitable infrastructure may help expand AI-assisted deprescribing across practice settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.